Display options
Cite
Kroemer G, Galluzzi L. Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology. 2015;4(7):e1058037doi: 10.1080/2162402X.2015.1058037.
Kroemer, G., & Galluzzi, L. (2015). Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology, 4(7), e1058037. https://doi.org/10.1080/2162402X.2015.1058037
Kroemer, Guido, and Galluzzi, Lorenzo. "Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark." Oncoimmunology vol. 4,7 (2015): e1058037. doi: https://doi.org/10.1080/2162402X.2015.1058037
Kroemer G, Galluzzi L. Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology. 2015 Jun 03;4(7):e1058037. doi: 10.1080/2162402X.2015.1058037. eCollection 2015 Jul. PMID: 26140249; PMCID: PMC4485790.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2015 Jun 03;4(7):e1058037. doi: 10.1080/2162402X.2015.1058037. eCollection 2015 Jul.

Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.

Oncoimmunology

Guido Kroemer, Lorenzo Galluzzi

Affiliations

  1. INSERM ; U1138; Paris, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France ; Equipe 11 labellisée Ligue contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; Metabolomics and Cell Biology Platforms; Gustave Roussy Comprehensive Cancer Institute ; Villejuif, France ; Pôle de Biologie, Hôpital Européen Georges Pompidou; AP-HP ; Paris, France.
  2. INSERM ; U1138; Paris, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France ; Equipe 11 labellisée Ligue contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; Gustave Roussy Comprehensive Cancer Institute ; Villejuif, France.

PMID: 26140249 PMCID: PMC4485790 DOI: 10.1080/2162402X.2015.1058037

Abstract

Results from recent clinical trials demonstrate that a combinatorial immunotherapeutic regimen based on 2 distinct checkpoint blockers, namely, the CTLA4-targeting agent ipilimumab and the PD-1-specific molecule nivolumab, causes objective responses in a majority of subjects with advanced melanoma. These findings revolutionize the treatment of a neoplasm that was considered incurable until recently. Nonetheless, announcing the defeat of melanoma appears premature. Indeed, a sizeable fraction of patients does not respond to ipilimumab plus nivolumab, and the long-term efficacy of this immunotherapeutic regimen has not yet been investigated. Moreover, many patients experience severe side effects, calling for the development of strategies that uncouple the efficacy of ipilimumab plus nivolumab from their toxicity.

Keywords: CTLA4; Opdivo™; PD-1; PD-L1; Yervoy™; pembrolizumab

References

  1. N Engl J Med. 2013 Jul 11;369(2):122-33 - PubMed
  2. Oncoimmunology. 2014 May 01;3:e28344 - PubMed
  3. Oncoimmunology. 2014 Jan 1;3(1):e28185 - PubMed
  4. Oncoimmunology. 2014 Dec 15;3(10):e958952 - PubMed
  5. Oncoimmunology. 2013 Jul 1;2(7):e24850 - PubMed
  6. Lancet. 2014 Sep 20;384(9948):1109-17 - PubMed
  7. Cell Res. 2015 Feb;25(2):208-24 - PubMed
  8. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  9. J Clin Oncol. 2012 Jul 20;30(21):2691-7 - PubMed
  10. N Engl J Med. 2015 May 21;372(21):2006-17 - PubMed
  11. Oncoimmunology. 2013 Jun 1;2(6):e23972 - PubMed
  12. Oncoimmunology. 2014 Jan 1;3(1):e27297 - PubMed
  13. Oncoimmunology. 2013 Jan 1;2(1):e22789 - PubMed
  14. Oncotarget. 2014 Dec 30;5(24):12472-508 - PubMed
  15. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  16. Oncoimmunology. 2014 Dec 13;3(9):e954956 - PubMed
  17. Oncoimmunology. 2014 May 15;3:e28440 - PubMed
  18. Oncoimmunology. 2014 Dec 21;3(11):e963413 - PubMed
  19. N Engl J Med. 2015 Jun 25;372(26):2521-32 - PubMed
  20. J Clin Oncol. 2014 Apr 1;32(10):1020-30 - PubMed
  21. Lancet Oncol. 2015 Apr;16(4):375-84 - PubMed
  22. Oncoimmunology. 2013 Sep 1;2(9):e26535 - PubMed
  23. N Engl J Med. 2013 Apr 4;368(14 ):1365-6 - PubMed
  24. Oncoimmunology. 2014 Jun 03;3:e29030 - PubMed
  25. Oncoimmunology. 2013 May 1;2(5):e24238 - PubMed
  26. Lancet Oncol. 2015 May;16(5):522-30 - PubMed
  27. Oncoimmunology. 2014 Jun 25;3:e29244 - PubMed
  28. Oncoimmunology. 2013 Dec 1;2(12):e26621 - PubMed
  29. Oncoimmunology. 2013 Jun 1;2(6):e25396 - PubMed
  30. N Engl J Med. 2013 Jul 11;369(2):187-9 - PubMed
  31. PLoS One. 2013;8(1):e53745 - PubMed
  32. Oncoimmunology. 2014 Dec 21;3(11):e967147 - PubMed
  33. N Engl J Med. 2012 Jun 28;366(26):2455-65 - PubMed

Publication Types